Myomo (MYO) vs TELA Bio (TELA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Myomo (MYO) has outperformed TELA Bio (TELA) over the past year, gaining 23.3% versus a loss of 25.0%. Over five years, MYO leads with a -89.3% price change compared with -91.2% for TELA. Myomo is the larger company by market cap ($56.6 million vs $50.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MYO | TELA |
|---|---|---|
| Share price | $1.43 | $1.11 |
| Market cap | $56.64M | $50.11M |
| 1-day change | +1.42% | +5.71% |
| YTD return | +57.14% | -5.93% |
| 1-year return | +23.28% | -25.00% |
| 5-year return | -89.28% | -91.19% |
| EPS (TTM) | $-0.35 | $-0.77 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.89 | $1.56 |
| 52-week low | $0.605 | $0.501 |
| Distance from 52-week high | -24.14% | -28.85% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +224.48% | +87.39% |
| Average volume | 489.85K | 215.49K |
| Shares outstanding | 39.61M | 45.14M |
| Employees | 194 | 218 |
| Sector | Health Care | Health Care |
| Industry | Industrial Specialties | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MYO has outperformed TELA by 48.3 percentage points over the past year.
About Myomo
MYO stock →Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living.
Health Care · Industrial Specialties · 194 employees
About TELA Bio
TELA stock →TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene, polyglycolic acid, and polylactic-co-glycolic acid designed to be used in laparoscopic and robotic-assisted hernia surgical repairs.
Health Care · Medical/Dental Instruments · 218 employees
MYO vs TELA FAQ
Which is bigger, Myomo or TELA Bio?
Myomo (MYO) is larger, with a market capitalization of $56.64M compared with $50.11M for TELA Bio (TELA).
Which stock has performed better over the past year, MYO or TELA?
MYO returned +23.28% over the past 12 months, compared with -25.00% for TELA (price return, excluding dividends). Past performance does not predict future results.
Are Myomo and TELA Bio in the same industry?
Both are in the Health Care sector, but in different industries: Industrial Specialties for Myomo and Medical/Dental Instruments for TELA Bio.